Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.

World journal of urology

Volumn 23, Issue 4, 2005, Pages 248-252

  Zinner, Norman ^a   Tuttle, John ^a   Marks, Leonard ^a  

^a Western Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOFURAN DERIVATIVE; DARIFENACIN; MANDELIC ACID DERIVATIVE; MUSCARINIC M3 RECEPTOR; OXYBUTYNIN; PYRROLIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE INCONTINENCE; URODYNAMICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; PYRROLIDINES; RECEPTOR, MUSCARINIC M3; TREATMENT OUTCOME; URINARY INCONTINENCE; URODYNAMICS;

EID: 32044463731     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-005-0507-3     Document Type: Article

References (0)